ANNOUNCEMENTS

Advanced Nephrology: Nephrology for the Consultant
Advanced Nephrology: Nephrology for the Consultant, sponsored by the Division of Nephrology, Department of Medicine, University of California, San Diego, CA, will be held February 6-8, 1997, at The Hotel del Coronado, Coronado (San Diego), CA. The registration fee is $395 for physicians in practice, and $175 for residents/fellows. This course is designated for 17 hours of AMA Category I Accreditation. For information, contact Shirley Kolkey, Course Coordinator, at 1660 Hotel Circle North, #220, San Diego, CA 92108. Telephone: 619-299-6673; fax: 619-299-6675.

National Kidney Foundation Sixth Annual Spring Clinical Nephrology Meeting—Consultative Nephrology Program
The National Kidney Foundation Spring Clinical Nephrology Meetings offer six separate programs targeted toward nephrologists, renal and non-renal dietitians, social workers, nurses and technicians. There will also be a special two-day program designed for primary care physicians in association with the Texas Academy of Family Physicians. The National Kidney Foundation’s (NKF) Sixth Annual Spring Clinical Nephrology Meeting—Consultative Nephrology Program will be held April 17–20, 1997 at the Wyndham Anatole Hotel in Dallas, TX. For registration information, call 1-800-622-9010.

Nephrology—1997
Nephrology—1997 will be held May 4–9, 1997, at the Copley Plaza Hotel, Boston, MA. The program is sponsored by the Department of Continuing Education, Harvard Medical School, and is directed by Burton D. Rose, MD. The objective of this course is to review for the practicing nephrologist the pathophysiologic and clinical advances in the major areas of nephrology, including glomerular disease, fluid and electrolyte disorders, hypertension, dialysis, and renal transplantation. For a brochure contact: Professional Meeting Planners, 5 Central Sq, Ste 201, Stoneham, MA 02180. Telephone: 1-800-378-6857 or 617-279-9887; fax: 617-279-9875; e-mail: PMPMeeting@aol.com.

42nd Annual Congress of the Japanese Society for Dialysis Therapy
The 42nd Annual Congress of the Japanese Society for Dialysis Therapy will be held Friday, July 18 to Sunday, July 20, 1997 at the Royton Sapporo (main), Kita 1-jo, Nishi 11-chome, Chuo-ku, Sapporo, Hokkaido, 060 Japan. The Congress is open to foreign participants to submit and present their papers in specially provided English sessions. The deadline for abstract submissions is January 16, 1997, and for hotel reservations is March 31, 1997. Abstract forms will be delivered upon request. Paper presenters will be exempted from payment for registration and hotel accommodation in Sapporo (maximum 3 nights). According to selection by the International Scientific Committee of the Society, a maximum of 20 paper presenters who do not exceed 40 years of age at the Congress will receive a ¥100,000 award from the Society. For further information and request for abstract forms, contact Tetsuo Agishi, M.D., Ph.D., Congress President, Kidney Center, Tokyo Women’s Medical College, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan. Telephone: (main) 81-3-3358-9582 (sub) 81-3-5361-8028; fax: (main) 81-3-3358-9582 (sub) 81-3-5361-8028; e-mail: na6t-ag8@asahi-net.or.jp and Internet URL: http://www.asahi-net.or.jp/~na6t-ag8/.

Fifth Basic Sciences Symposium of the Transplantation Society
The Fifth Basic Sciences Symposium of the Transplantation Society will be held at the Chautauqua Institution, Chautauqua, NY, on September 6–11, 1997. Distinguished plenary speakers will update the most relevant topics of transplantation biology, which will be enhanced by oral and poster presentations by interested participants on the following subjects: T-Cell Stimulation and Co-stimulation, T-Cell Signalling Mechanisms, Immune Privilege, Tolerance, Chimerism and Bone Marrow Transplantation, Immunosuppression, Alloreactivity and Rejection, and Newer Experimental Models. Registration fees and costs of board and lodging have been kept to reasonable levels to encourage participation. The Chautauqua Institution has an esteemed historical, educational, and cultural tradition and is a splendid setting for a scholarly retreat, yet one within easy reach of Buffalo, NY. The deadline for submission of abstracts is January 31, 1997. For further information, contact R. Cunningham, Ph.D., The Ernest Wittebisky Center for Immunology, School of Medicine and Biomedical Sciences, 233 Sherman Hall, 3435 Main Street, Buffalo, NY 14214-3078. Telephone: 716-829-2901; fax: 716/829-2158; email: reunning@ubmedb.buffalo.edu.
Every month the most influential journal in the field* will be delivered to you, when you subscribe to Journal of the American Society of Nephrology (JASN).

We’ve got you covered no matter your specialty:

- Nephrology
- Internal Medicine
- Transplant Surgery

We’ll keep you on the cutting edge of the newest concepts, newest discoveries, and newest research in this rapidly changing field.

Recent Topics in JASN:
- Renal Functional Reserve in Kidney and Heart Transplant Donors and Recipients
- Cardiovascular Disease after Renal Transplantation
- Mechanism of the Antiproteinuric Effect of Cyclosporine in Membranous Nephropathy
- Effect of rh Insulin-like Growth Factor-1 on the Inflammatory Response to Acute Renal Injury

Put the #1 Journal in Nephrology to work for you. Subscribe to JASN today, and join the many innovative scientists and physicians who get a better understanding of kidney functions along with the means to improve medical care of individuals with kidney diseases.

* Ranks first for impact among journals in the urology and nephrology category (Science Citation Index, 1994)
Every month, you get comprehensive, all-inclusive coverage with the unique blend of articles, reviews, and lively commentary in The Journal of Urology. Be in touch with the developing developments and innovative clinicians and researchers who shape the way you practice every day. Each issue brings you an average of:

1 review article summarizing state-of-the-art research and practice.
40 original clinical articles addressing your primary concerns... including urologic neurology and urodynamics.
10 pediatric urology articles
12 case reports filled with practical diagnostic and management articles and developments in innovative clinical procedures.
15 investigative articles bringing you up-to-date on progress in solving urology's toughest clinical and theoretical problems.
75 abstracts to keep you abreast of the latest, most significant developments in every area of urology.

And now, The Journal of Urology is even more valuable to your practice. Earn up to 24 hours of Category 1 credit, offered by the American Urological Association Office of Education. For a small registration fee, you receive answer sheets for the 5 questions published in each issue based on that month's articles. Subscribe to The Journal of Urology now and receive more than 5,000 pages of the latest information for urologists and the opportunity to earn CME credits at your convenience.

4 Easy Ways To Order

Call 1-800-638-6423
Outside the U.S.: 410-528-8555
London: 171-385-2357
Hong Kong: 852-2610-2339
Tokyo: 03-5809-5400

Fax 410-528-8596
E-Mail custserv@wwilkins.com

Mail order form today to:
Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21206-9990

Members of the AUA receive the Journal as a benefit of membership.
The 1996 ASN Board Review
Course has Expanded to...

The 1997 ASN
Board Review
and Update
August 23-29, 1997
Palace Hotel
San Francisco

S
ince board certification exams are given annually, the ASN will now offer its
board review each year. The enormously successful 1996 course program has
been expanded for 1997 to include an update for more senior nephrologists.
Advanced workshops will be presented concurrently with the main review. This
new format will allow you to shape your own course. Certified nephrologists may
now obtain what information they need from the board review and choose to attend
some or all of the advanced workshops. Highlights of the 1997 program include:

Board Review:
• 48 hours of teaching and 48
continuing medical education
(CME) credits
• Three full days, three half days
(more time to see San
Francisco)
• New topics: Pregnancy,
Resistant Hypertension
• Audience Response Pads
• Two exams

Advanced Workshops:
• 15 additional hours of teaching
• Ten 1½ - hour workshops with
ten new topics
• Cutting-edge updates

Course Director:
Robert G. Narins, M.D.

Faculty:
T. Andreoli, Little Rock, Ark.
A. Arien, San Francisco, Calif.
G. Appel, New York, N.Y.
P. August, New York, N.Y.
H. Black, Chicago, Ill.
J. Breyer, Nashville, Tenn.
F. Coe, Chicago, Ill.
M. R. First, Cincinnati, Ohio
*R. Glassock, Lexington, Ky.
T. Golper, Little Rock, Ark.
M. Halperin, Toronto, Ont.
K. Hruska, St. Louis, Mo.
R. Johnson, Seattle, Wash.
B. Kahan, Houston, Texas
N. Kaplan, Dallas, Texas
S. Moe, Indianapolis, Ind.
B. Myers, Stanford, Calif.
B. Peraino, Pittsburgh, Pa.
M. Pohl, Cleveland, Ohio
H. Rennke, Boston, Mass.
B. Rose, Boston, Mass.
R. Rubin, Boston, Mass.
J. Verbalis, Washington, D.C.
D. Warnock, Birmingham, Ala.
C. Wilcox, Washington, D.C.
R. Zager, Seattle, Wash.

* Denotes ASN past president.

Enrollment is limited!
For information or to request a brochure, contact:

American Society of Nephrology
Telephone: 202/857-1190  •  Fax: 202/429-5112  •  E-mail: asn@sba.com
The last word in alcoholism research...

ALCOHOLISM
Clinical and Experimental Research

The Official Journal of The Research Society on Alcoholism and International Society for Biomedical Research on Alcoholism
Editor: Marcus A. Rothschild, M.D.

Here's your chance to complete your professional reading list with the most comprehensive, most significant journal in the field of alcoholism studies—Alcoholism: Clinical and Experimental Research.

Nine times a year, you'll get original research articles on alcoholism, alcohol-induced syndromes, and organ damage. The basic sciences—including biochemistry, experimental neurology and psychology, psychiatry, and physiology—are all represented, as are clinical science (including epidemiology and work with human subjects) and the therapeutic professions. Expert critiques of timely publications, abstracts from important international meetings, and society news and announcements complete this invaluable update.

Now entering its 21st year, Alcoholism continues its popular "Symposium" feature, inviting leading authorities to survey specific—and critical—topics.

As one of the leading journals in the substance abuse category, Alcoholism attracts some of the finest minds in research today. Distinguished editors from The Research Society on Alcoholism carefully select all the important results you need for your laboratory or office work.

SUBSCRIBE TODAY!

Please enter my subscription to Alcoholism: Clinical and Experimental Research. Nine times a year.

☐ Individual $200/year ☐ Institutional $380/year
☐ In-training* $120/year
☐ New Subscription ☐ Renewal

Subtotal: __________________________

☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ American Express ☐ MasterCard ☐ VISA ☐ Discover
Card #: ___________________________ Exp. date ____________

Signature or P.O. # ___________________________

Return coupon to:
Williams & Wilkins
A WAVERLY COMPANY
P.O. Box 23291, Baltimore, MD 21203-9990

For credit card orders, call TOLL FREE: 1-800-638-6423 in North America. Outside North America, fax 1-410-361-8048 or call one of our international offices: Tokyo (03) 5689-5400, London 0171-385-2357, Hong Kong 852-2610-2339. INTERNET E-mail: custserv@wwilkins.com
Home page: http://www.wwilkins.com

©DG 1996

* Please indicate institution/status

ALC 57651 Printed in USA

Rates valid through October 31, 1997.
No other diltiazem is therapeutically equivalent

The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving CARDIZEM CD up to 360 mg with rates in placebo patients shown for comparison.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>CARDIZEM CD (n=507)</th>
<th>Placebo (n=501)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5.4%</td>
<td>5.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3.0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>3.0%</td>
<td>1.3%</td>
</tr>
<tr>
<td>AV Block First Degree</td>
<td>3.3%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Edema</td>
<td>2.7%</td>
<td>1.7%</td>
</tr>
<tr>
<td>ECG Abnormality</td>
<td>1.6%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Aspirin</td>
<td>1.4%</td>
<td>1.7%</td>
</tr>
</tbody>
</table>

In clinical trials of CARDIZEM CD capsules, CARDIZEM tablets, and CARDIZEM SR capsules involving over 3,200 patients, the most common events (ie, greater than 1%) were edema (4.9%), headache (4.3%), dizziness (3.5%), asthenia (2.6%), and angina pectoris (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%), and rash (1.2%).

In addition, the following events were reported infrequently (less than 1%) in hypertension trials:

- Cardiovascular: Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, palpitations, syncope, tachycardia, ventricular tachycardia, ventricular extrasystoles
- Nervous System: Delirium, amnesia, depression, gait disturbance, hallucinations, insomnia, nervousness, paresthesia, confusion.
- Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysphagia, dyspepsia, mild elevations of SGOT, BBS1, DLD, and alkaline phosphatase (see hepatic warnings). thirst, vomiting, weight increase
- Dermatologic: Acne, dermatitis, pruritus, urticaria
- Other: Anosmia, CPEP, increased appetite, nausea, purpura, pyrexia, rash, rhinitis, salivation, skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, extramural dermatitis, erythema multiforme, exfoliative dermatitis, hemolytic anemia, hemolytic-uremic syndrome, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarthritis, pain, pigmentary changes, pustule, rash, retinopathy, sepsis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vasculitis, xerostomia, xerosis, and xerophthalmia

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM, including, alopecia, angioedema (including facial or periorbital edema), asthenia, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis, erythema multiforme, exfoliative dermatitis, hemolytic anemia, hemolytic-uremic syndrome, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarthritis, pain, pigmentary changes, pustule, rash, retinopathy, sepsis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vasculitis, xerostomia, xerosis, and xerophthalmia.

References:
Benefits of a Non-Dihydropyridine CCB*

A UNIQUE HEMODYNAMIC AND SAFETY PROFILE DIFFERENT FROM DIHYDROPYRIDINIDES

Effective 24-hour control of hypertension or angina
- Reduces blood pressure with no reflex tachycardia
- Increases exercise tolerance, reduces vasospasm, and decreases heart rate in angina

Well tolerated control regardless of age or gender
- A side-effect discontinuation rate comparable to placebo
- Most commonly reported side effects are headache (5.4%), bradycardia (3.3%), first-degree AV block (3.3%), dizziness (3.0%), edema (2.6%), ECG abnormality (1.6%), and asthenia (1.8%)

True 24-hour control from a unique patented delivery system
- No other diltiazem is therapeutically equivalent to Cardizem CD

*Cardizem CD is a benzothiazepine calcium channel blocker.
† In clinical trials with Cardizem CD.
‡ FDA does not, at this time, consider other diltiazems to be therapeutically equivalent because bioequivalence has not been demonstrated through appropriate studies.

Please see brief summary of prescribing information on adjacent page.

FOR HYPERTENSION OR ANGINA

ONCE-A-DAY CARDIZEM® CD
(diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

No other diltiazem is therapeutically equivalent†